Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial
Sorena Kiani‐Alikhan(Royal Free London NHS Foundation Trust), William R. Lumry(The University of Texas Southwestern Medical Center)
The Journal of Allergy and Clinical Immunology In Practice
December 18, 2023
Cited by 25
Related Papers
Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis
|New England Journal of Medicine|2017|171
International Consensus on the Use of Genetics in the Management of Hereditary Angioedema
|The Journal of Allergy and Clinical Immunology In Practice|2019|80
Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study
|Clinical and Translational Allergy|2021|54